In addition to breast cancer susceptible gene (BRCA) deficiency, heightened sensitivity to PARP inhibition has also been observed in cells with other genetic lesions that affect HR, including phosphatase and tensin homolog (PTEN) deficiency, ataxia telangiectasia mutated (ATM) deficiency, and Aurora A overexpression14–16. This evidence concerns the gene ATM and breast cancer.